Alzheimer: Differences in Men & Women & New Protein Discoveries
Groundbreaking research is revealing that Alzheimer’s disease manifests differently in men and women. The findings stem from the polAris project, conducted by the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) in association with the Hospital Clínico de Barcelona, and funded by the Rosa Maria Vivar Foundation. Analyses have detected differing levels of proteins between the sexes – some shared, but crucially, others unique. Specifically, women in the study exhibited a higher presence of components linked to inflammatory processes.
Sex-Specific Protein Signatures
The polAris project involved over 250 participants – 189 with Alzheimer’s and 64 healthy individuals – and analyzed more than 100 proteins in cerebrospinal fluid, a key indicator of brain health. Researchers identified approximately 40 proteins elevated in individuals with Alzheimer’s, potentially linking them to neurodegeneration, inflammation, neuronal damage, and other alterations. Currently, only two proteins – tau and beta amyloid – are clearly associated with Alzheimer’s, but existing pharmaceutical treatments have limited effectiveness.
These initial discoveries could pave the way for more personalized treatments tailored to individual profiles, and potentially bring researchers closer to a cure. Margarita Oliva, president of the Rosa Maria Vivar Foundation, explained, “It’s a super interesting result because it suggests we may find different causes and, surely, different therapeutic targets.”
Disproportionate Impact on Women
Oliva highlighted that Alzheimer’s disease has a greater incidence in women, who comprise approximately two-thirds of those affected. “Addressing it as if they were different subjects is innovative and interesting,” she stated. The research suggests the disease manifests differently in men and women, leading to the possibility of targeted therapies. “Imagine we find a medication that corrects a neuroinflammation problem: we would be curing Alzheimer’s disease for women,” celebrated Oliva.
Oliva emphasized that the foundation’s primary goal is to find a cure. While a cure isn’t imminent – requiring years of further work – the polAris project provides a crucial starting point. Next steps include finalizing the scientific report and reconfirming the results in laboratories. “From there, we could start talking about what the appropriate medication would be,” she noted. Securing funding is essential to continue this work, with a goal of obtaining funding for one to two more years of research.
A Growing Global Challenge
Currently, an estimated 50 million people worldwide are affected by dementia, with projections indicating a significant increase in cases in the coming decades. Oliva stressed the urgency of Alzheimer’s research, stating that failure to find a cure or prevention method will create an “unmanageable problem” due to the sheer number of individuals affected. “We don’t want to be late,” she asserted, adding that the research has the potential to benefit society on a global scale.
The Rosa Maria Vivar Foundation will also actively seek out and support other national and international projects aimed at curing Alzheimer’s and accelerating the timeline for achieving this goal.
Frequently Asked Questions
What did the polAris project discover?
The polAris project discovered that Alzheimer’s disease affects men and women differently, with differing levels of proteins present in the cerebrospinal fluid of individuals with the disease. Women showed a higher presence of proteins associated with inflammation.
How many people participated in the study?
The study included over 250 participants, consisting of 189 individuals with Alzheimer’s disease and 64 healthy individuals.
What is the foundation’s ultimate goal?
The Rosa Maria Vivar Foundation’s primary goal is to find a cure for Alzheimer’s disease.
Given these new insights into the differing biological pathways of Alzheimer’s in men and women, how might this influence future approaches to diagnosis and treatment?